Trial record 1 of 1 for:
nct 00778206
PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry
This study is currently recruiting participants.
Verified November 2011 by BioMarin Pharmaceutical
Sponsor:
BioMarin Pharmaceutical
Information provided by:
BioMarin Pharmaceutical
ClinicalTrials.gov Identifier:
NCT00778206
First received: October 21, 2008
Last updated: November 30, 2011
Last verified: November 2011
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | October 21, 2008 | ||||
| Last Updated Date | November 30, 2011 | ||||
| Start Date ICMJE | September 2008 | ||||
| Estimated Primary Completion Date | September 2023 (final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures ICMJE | Not Provided | ||||
| Original Primary Outcome Measures ICMJE | Not Provided | ||||
| Change History | Complete list of historical versions of study NCT00778206 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE | Not Provided | ||||
| Original Secondary Outcome Measures ICMJE | Not Provided | ||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title ICMJE | PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry | ||||
| Official Title ICMJE | PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry | ||||
| Brief Summary | The objective of this study is to evaluate the safety of long-term treatment with Kuvan. |
||||
| Detailed Description | The PKUDOS program is a voluntary, multicenter, strictly observational program for patients with PKU who have either received Kuvan therapy, or currently receive Kuvan, or intends to begin receiving Kuvan therapy within 90 days of entering the registry. |
||||
| Study Type ICMJE | Observational | ||||
| Study Design ICMJE | Observational Model: Cohort Time Perspective: Prospective |
||||
| Target Follow-Up Duration | Not Provided | ||||
| Biospecimen | Not Provided | ||||
| Sampling Method | Non-Probability Sample | ||||
| Study Population | Diagnosis of Phenylketonuria with hyperphenylalaninemia |
||||
| Condition ICMJE |
|
||||
| Intervention ICMJE | Drug: Sapropterin Dihydrochloride
|
||||
| Study Group/Cohort (s) |
|
||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Recruiting | ||||
| Estimated Enrollment ICMJE | 3500 | ||||
| Completion Date | Not Provided | ||||
| Estimated Primary Completion Date | September 2023 (final data collection date for primary outcome measure) | ||||
| Eligibility Criteria ICMJE | PKUDOS Registry Inclusion Criteria:
Exclusion Criteria:
PKU MOMS Subregistry Inclusion Criteria:
Exclusion Criteria:
|
||||
| Gender | Both | ||||
| Ages | Not Provided | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts ICMJE |
|
||||
| Location Countries ICMJE | United States, Puerto Rico | ||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT00778206 | ||||
| Other Study ID Numbers ICMJE | PKUDOS-01, PKUDOS Registry | ||||
| Has Data Monitoring Committee | No | ||||
| Responsible Party | BioMarin Pharmaceutical Inc. | ||||
| Study Sponsor ICMJE | BioMarin Pharmaceutical | ||||
| Collaborators ICMJE | Not Provided | ||||
| Investigators ICMJE |
|
||||
| Information Provided By | BioMarin Pharmaceutical | ||||
| Verification Date | November 2011 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||